SELPERCATINIB - Generic Drug Details

What are the generic sources for selpercatinib and what is the scope of patent protection?

Selpercatinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in two NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selpercatinib has one hundred and forty-seven patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for SELPERCATINIB

International Patents:	147
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	31
What excipients (inactive ingredients) are in SELPERCATINIB?	SELPERCATINIB excipients list
DailyMed Link:	SELPERCATINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SELPERCATINIB

Constraining patent/regulatory exclusivity:

10,112,942*PED

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

10,112,942*PED

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SELPERCATINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oklahoma	EARLY_PHASE1
Presbyterian Health Foundation	EARLY_PHASE1
Fujian Medical University	PHASE4

See all SELPERCATINIB clinical trials

Pharmacology for SELPERCATINIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors P-Glycoprotein Inhibitors Rearranged during Transfection (RET) Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SELPERCATINIB

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for SELPERCATINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RETEVMO	Capsules	selpercatinib	40 mg and 80 mg	213246	1	2024-05-08

US Patents and Regulatory Information for SELPERCATINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-003	Apr 10, 2024		RX	Yes	No	10,172,851*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-001	May 8, 2020		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-001	May 8, 2020		RX	Yes	No

EU/EMA Drug Approvals for SELPERCATINIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Retsevmo	selpercatinib	EMEA/H/C/005375Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment	Authorised	no	no	no	2021-02-11

International Patents for SELPERCATINIB

Country	Patent Number	Title	Estimated Expiration
Argentina	113760
Spain	2805087
China	118319866	包含RET激酶抑制剂的制剂 (Formulations comprising RET kinase inhibitors)
Japan	6945070
Japan	2023134580	ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５－Ａ］ピリジン化合物 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Taiwan	202410896
Portugal	3523301

Selpercatinib Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is selpercatinib’s market footprint by indication and geography?

Selpercatinib (brand: Retevmo) is an oral, targeted therapy for RET-driven cancers. Its market footprint is defined by (1) broad adoption in RET-mutant non-small cell lung cancer (NSCLC) and (2) a growing contribution from RET-altered solid tumors, with the largest commercial scale historically coming from NSCLC. Commercial geography is led by the US, with meaningful demand in Europe and Japan where regulatory approvals and payer coverage translated into uptake.

Commercial anchor indications shaping sales mix

• RET-mutant NSCLC (first-line and later-line in different label configurations)
• RET fusion-positive NSCLC
• RET-altered thyroid cancer (advanced or metastatic; label structure varies by jurisdiction)
• Other RET-altered solid tumors under tumor-agnostic or tissue-agnostic label language, depending on territory

(Indication scope is reflected in the approved label and common payer uptake patterns for Retevmo.) [1], [2]

How have approvals and label expansions driven adoption and pricing leverage?

Selpercatinib’s sales trajectory tracks the cadence of regulatory expansion and line-of-therapy shifts. Each incremental approval tends to expand the addressable patient base and increases prescriber confidence, which supports formulary inclusion and reduces access friction. The commercial outcome is visible in sustained revenue growth through the main adoption windows after major label milestones. [1], [2]

Key market-driving events in the public record include:

• US initial approval for RET-mutant NSCLC and later label expansions under the FDA’s RET program.
• Broader metastatic/advanced tumor coverage through additional regulatory clearances across RET-altered cancers.
• Ongoing label updates that adjust eligibility by prior lines and mutation or fusion status.

These events are reflected in the structured indications shown in the FDA label. [1]

What does the financial trajectory show about revenue sustainability?

Public company reporting for selpercatinib’s manufacturer (Eli Lilly and Company for Retevmo after licensing and acquisition structures) shows that revenue has been sustained through:

• continued uptake in core RET NSCLC settings
• steady expansion into adjacent RET-altered indications
• retention of market position against competing RET inhibitors

The financial trajectory over the last several reported periods indicates that Retevmo has remained an established oncology revenue franchise rather than a short-cycle launch product. This is consistent with the long-tail chronic nature of targeted therapy reimbursement once patients are identified and treated. [3]

Revenue drivers that support sustainability

• Patient identification infrastructure (testing for RET fusions/mutations) that increases the number of eligible patients captured in practice
• Dosing practicality (oral chronic therapy) that reduces treatment-site dependence relative to infusion regimens
• Relative efficacy and tolerability profile supporting continued use after market entry

(Clinical efficacy and safety structure are reflected in the approved label.) [1]

How does the competitive landscape affect pricing, share, and retention?

Selpercatinib competes primarily with other RET-targeted agents and, secondarily, with broader lung cancer targeted and immuno-oncology regimens depending on line and biomarkers. Competitive pressure affects:

• Net pricing through payer negotiations and contracting
• Sequencing decisions (which RET agent is used first)
• Switch rates when efficacy or tolerability differences matter for subpopulations

Competitive pressure points relevant to market dynamics

• Class competition within RET inhibition: Multiple RET inhibitors target similar biomarker-defined populations, so differentiation influences patient selection and payer coverage.
• Line-of-therapy constraints: As labels expand to earlier lines, competitive intensity increases because multiple agents can be viable in the same treatment window.
• Access dynamics: Formularies often treat targeted oncology similarly, but rebate structures and step edits can shift outcomes month-to-month.

(Competitive landscape context is reflected in the fact that RET remains a distinct biomarker category with multiple available targeted options.) [1], [2]

What are the commercialization levers that translate into cash-flow impact?

Selpercatinib’s financial performance is driven by commercialization mechanics that directly map to payer adoption and prescribing behavior.

1) Biomarker testing penetration

• Higher RET testing frequency increases the share of eligible patients identified.
• Testing outcomes feed directly into treatment rates and refill persistence.

2) Payer coverage and contracting

• Oncology targeted drugs typically face systematic formulary tiering, prior authorization, and step therapy frameworks.
• Durable contracts influence whether growth is “new volume” or “net price” driven.

3) Treatment persistence and dose management

• As with many targeted therapies, persistence matters more than one-time dosing.
• Label guidance influences clinical handling of dose reductions or interruptions, affecting real-world continuity.

Safety and dose management guidance are detailed in the FDA label. [1]

How does the label and safety profile influence market adoption curves?

Adoption curves in oncology targeted therapy are highly sensitive to safety handling requirements, especially for RET inhibitors. Selpercatinib’s label includes:

• monitoring recommendations
• dose interruption and reduction logic for adverse events
• warnings and precautions that shape onboarding for new prescribers and center formularies

These label-specific operational requirements affect time-to-adoption and early uptake velocity. [1]

What policy and reimbursement factors shape net revenue?

Net revenue is influenced by contracting practices across:

• US commercial insurance and Medicare Part D/managed care
• European national health systems with HTA-driven access
• Japan reimbursement frameworks that can vary by evidence maturity and pricing rules

While the public sources here focus on label content and company financial disclosures, the market mechanism is consistent: payer access governs realized revenue more than list price. The manufacturer’s annual disclosures track the realized performance of Retevmo. [3]

What does the market likely price and segment like versus peers?

RET inhibitors typically price as precision oncology drugs with net pricing influenced by rebate structures tied to volume and contract terms. In practice, segmentation is driven by:

• biomarker-positive NSCLC and thyroid cancer populations
• line-of-therapy and prior treatment history
• geographic coverage and HTA outcomes

These segments determine whether a manufacturer can grow by expanding treated patients or must rely on net price retention.

How is selpercatinib positioned financially versus pipeline and portfolio priorities?

From a portfolio perspective, Retevmo competes for attention and resources against other marketed oncology franchises and pipeline assets. Financial trajectory is therefore a function of:

• marketing and medical affairs spend efficiency (field adoption)
• competitive displacement risk in RET lines
• pipeline lifecycle events (replacement risk if a next-gen RET inhibitor or off-target competitors capture share)

This dynamic is reflected in how manufacturers disclose oncology franchise performance as part of broader segment results. [3]

Key data: what is publicly documented about selpercatinib’s commercialization basis?

Approved product foundation (regulatory)

• FDA prescribing information for Retevmo lists the approved indications, safety warnings, and dosing guidance used by prescribers and payers for coverage decisions. [1]

Ongoing commercial reporting basis

• Manufacturer financial reporting provides revenue and business performance context for Retevmo as part of the company’s oncology portfolio. [3]

What is the expected direction of market share given ongoing competition?

Given the biomarker-defined nature of the market, share changes tend to come from:

• shifting use toward agents with favorable sequencing evidence in first-line and earlier-line settings
• payer-driven access changes if formulary position shifts among RET inhibitors
• persistence differences due to tolerability and adverse event management

Selpercatinib’s continued presence and adoption indicates its positioning remains strong in RET NSCLC, but competitive pressure can still moderate growth rates over time as the market matures. [1], [3]

---

Key Takeaways

• Selpercatinib’s market dynamics are driven by RET biomarker adoption and label expansion across RET-altered solid tumors, with NSCLC as the primary scale engine. [1], [2]
• Financial trajectory indicates a sustained oncology franchise profile, supported by treatment persistence, ongoing uptake, and contracting that sustains realized revenue over multiple reporting periods. [3]
• Competitive dynamics in RET inhibition influence net pricing and sequencing, which shapes incremental growth and can slow peak-cycle momentum as the market matures. [1], [2]
• Safety and dosing operational requirements in the FDA label affect onboarding and persistence, translating into real-world adoption pace and center-level formulary decisions. [1]

---

FAQs

1. What is selpercatinib primarily used for commercially?
   RET-driven cancers, with commercial scale anchored in RET-altered NSCLC and expanding coverage in RET-altered thyroid cancer and other solid tumors depending on label specifics. [1]

2. What drives continued demand after launch?
   Continued biomarker testing, ongoing patient identification, payer coverage stability, and persistence on oral targeted therapy. Label monitoring and dose management support continuity. [1]

3. How do label expansions typically affect revenue?
   They expand the addressable patient pool and increase prescriber confidence, supporting broader access and higher treated-volume potential. [1], [2]

4. What is the main competitive risk to selpercatinib?
   Other RET inhibitors and competitive sequencing in RET-positive lines of therapy, which can shift formulary placement and patient selection. [1], [2]

5. Where is the commercialization basis documented?
   The FDA-approved label defines indications, dosing, and safety handling that underpin payer and prescriber adoption; manufacturer disclosures provide the revenue and portfolio performance context. [1], [3]

---

References

[1] U.S. Food and Drug Administration. Retevmo (selpercatinib) prescribing information.
[2] European Medicines Agency. Retevmo (selpercatinib) EPAR and product information.
[3] Eli Lilly and Company. Financial reports and investor presentations referencing Retevmo revenue performance.